Medy-Tox Inc. (KOSDAQ:086900)

South Korea flag South Korea · Delayed Price · Currency is KRW
121,600
-1,200 (-0.98%)
Oct 30, 2025, 3:30 PM KST
-0.98%
Market Cap853.56B
Revenue (ttm)234.63B
Net Income (ttm)18.22B
Shares Out7.02M
EPS (ttm)2,832.89
PE Ratio42.92
Forward PE22.31
Dividend1,100.00 (0.90%)
Ex-Dividend DateSep 29, 2025
Volume34,942
Average Volume30,985
Open123,500
Previous Close122,800
Day's Range120,400 - 123,800
52-Week Range112,100 - 182,700
Beta0.28
RSI49.66
Earnings DateNov 13, 2025

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 705
Stock Exchange KOSDAQ
Ticker Symbol 086900
Full Company Profile

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 15.98 billion, an increase of 82.00%.

Financial Statements

News

There is no news available yet.